Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Thoracic 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Lung Neoplasms 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × seribantumab × Thoracic × Clear all
NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡